Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | KDM4A | O75164 | 2/20 | 0.51 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.51 |
| ▸ | KDM6B | O15054 | 1/20 | 0.51 |
| ▸ | KDM6A | O15550 | 1/20 | 0.51 |
| ▸ | TET3 | O43151 | 1/20 | 0.51 |
| ▸ | KDM4B | O94953 | 1/20 | 0.51 |
| ▸ | KDM5C | P41229 | 1/20 | 0.51 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.51 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.51 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.51 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.51 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20118919 | 0.84 | HAVCR2 (0.55) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL28507152 | 0.80 | KDM4E (0.59) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL16097617 | 0.80 | KDM4E (0.51) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL4061248 | 0.79 | KDM4E (0.66) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL20424050 | 0.78 | KDM4E (0.49) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL10465495 | 0.77 | KDM4E (0.54) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL3899127 | 0.77 | KDM4E (0.68) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL24716133 | 0.76 | KDM4E (0.62) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL69673 | 0.75 | KDM4E (0.77) | KDM4EL3MBTL1KDM4AEGLN1KDM6B | |
| SCHEMBL27891654 | 0.75 | HAVCR2 (0.55) | KDM4EL3MBTL1KDM4AEGLN1KDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841334-B2 | Compounds as cannabinoid receptor ligands and uses thereof | ABBVIE INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8546583-B2 | Pain, inflammatory or immune disorders, neurological disorders, cancers of the immune system, respiratory disorders, cardiovascular disorders, neuroprotection; e.g. 5-chloro-N-[(2Z)-5-(1-hydroxy-1-methylethyl)-3-[((cis)-3-methoxycyclobutyl)methyl]-4-methyl-1,3-thiazol-2(3H)-ylidene]-2-methoxybenzamide | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2222165-B1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC (US) | 2013-07-31 | — | — | EP | disclosed |
| CN-101925300-A | Novel compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LAB | 2010-12-22 | — | — | CN | disclosed |
| EP-2222165-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| CN-101454302-A | Thiazole compounds as cannabinoid receptor ligands and uses thereof | ABBOTT LAB (US) | 2009-06-10 | — | — | CN | disclosed |
| WO-2009067613-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093814-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | KDM4E 2095/4885L3MBTL1 2791/4885KDM4A 1486/4885 |
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | KDM4E 2535/4885L3MBTL1 3128/4885KDM4A 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.